Assessment of CD1c+CD14+ frequencies in their PBMCs upon inclusion (baseline), after anti-PD-L1 treatment but before surgery, and 10 weeks after surgery, enabled us to follow CD1c+CD14+ cell frequencies over time in NSCLC patients. This evidence concerns the gene CD14 and non-small cell lung carcinoma.